IXC — Invex Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$7.89m
- AU$3.87m
- AU$0.18m
Annual income statement for Invex Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.262 | 1.26 | 1.7 | 0.462 | 0.175 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 4.22 | 9.01 | 3.35 | 0.938 | 1.54 |
| Operating Profit | -3.95 | -7.75 | -1.64 | -0.477 | -1.37 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.95 | -7.75 | -1.64 | -0.477 | -1.35 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.95 | -7.75 | -1.64 | -0.477 | -1.35 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.95 | -7.75 | -1.64 | -0.477 | -1.35 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.95 | -7.75 | -1.64 | -0.477 | -1.35 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.053 | -0.103 | -0.022 | -0.006 | -0.018 |
| Special Dividends per Share |